Brzostek D, Piotrowska B, Droszcz W
Kliniki Pneumonologii Akademii Medycznej, Warszawie.
Pneumonol Alergol Pol. 1994;62(7-8):375-80.
In atopic asthmatics we have found, that 2 weeks of regular inhalative salbutamol monotherapy (200 mcg/qid) enhances BHR to histamine. Aim of this study was to evaluate the effect of this kind of ST on BHR in asthmatics under concomitant treatment with inhalative corticosteroids. We studied three group of patients: group 1--nonsymptomatic untreated asthmatics (n = 7); group 2--asthmatics under 2.42 +/- 1.3 years of continuous therapy with beclomethasone dipropionate (bdp, n = 8); group 3--in which bdp (200 mcg bid) was started at the same time as ST (n = 6). Spirometry and BHR challenge with histamine were performed before and after 2 weeks of ST. During the study the patients registered their PEF-values and asthma symptoms.
在特应性哮喘患者中，我们发现，2周的常规吸入沙丁胺醇单一疗法（200微克/每日4次）会增强对组胺的气道高反应性。本研究的目的是评估这种单一疗法对接受吸入性皮质类固醇联合治疗的哮喘患者气道高反应性的影响。我们研究了三组患者：第1组——无症状未治疗的哮喘患者（n = 7）；第2组——接受丙酸倍氯米松连续治疗2.42±1.3年的哮喘患者（n = 8）；第3组——在开始单一疗法的同时开始使用丙酸倍氯米松（200微克/每日2次）的患者（n = 6）。在单一疗法2周前后进行肺活量测定和组胺气道高反应性激发试验。在研究期间，患者记录其呼气峰值流速值和哮喘症状。
1）我们在任何一组中均未观察到单一疗法对症状评分、呼气峰值流速变异性或肺活量测定值有任何影响；2）在第1组中，单一疗法增加了气道高反应性（组胺激发试验中使组胺激发浓度为20时的呼气流量从0.939±0.577增加到0.387±0.337；Wilcoxon检验p<0.025）；3）在第2组和第3组中，单一疗法未引起气道高反应性的显著变化。
